688235 주식 개요 종양학 회사인 베이진은 미국, 중국, 유럽 등 전 세계에서 암 환자를 위한 다양한 치료법을 발굴하고 개발하는 기업입니다. 자세한 내용
생각, 링크 및 회사 내러티브를 캡처하세요.
가격 내역 및 성능
다음에 대한 주가 최고가, 최저가 및 변동 요약 BeiGene 과거 주가 현재 주가 US$161.22 52주 최고치 US$207.98 52주 최저치 US$98.50 베타 0.60 1개월 변경 -3.13% 3개월 변경 사항 10.32% 1년 변경 사항 18.54% 3년 변화 10.42% 5년 변화 n/a IPO 이후 변화 0.15%
최근 뉴스 및 업데이트
BeiGene, Ltd. Advances Leadership in CLL at ASH 2024 with New Data from Its Hematology Franchise Including BRUKINSA and Novel Pipeline Assets Dec 10
European Commission Approves BeiGene’s TEVIMBRA for First-Line Treatment of Advanced/Metastatic Esophageal Squamous Cell Carcinoma and Gastric or Gastroesophageal Junction Cancer Nov 27
BeiGene, Ltd. Announces Passing Away of Donald Glazer, A Board Member and the Chair of the Nominating and Corporate Governance Committee Oct 28
BeiGene, Ltd. to Report Q3, 2024 Results on Nov 13, 2024 Sep 30 BeiGene, Ltd. Appoints Shalini Sharp to Board of Directors and Member of the Audit Committee, Effective September 27, 2024 Sep 26
BeiGene Receives Israeli Ministry of Health Approval for TEVIMBRA® for the Treatment of Oesophageal Squamous Cell Carcinoma (OSCC) After Prior Chemotherapy Sep 17 더 많은 업데이트 보기
BeiGene, Ltd. Advances Leadership in CLL at ASH 2024 with New Data from Its Hematology Franchise Including BRUKINSA and Novel Pipeline Assets Dec 10
European Commission Approves BeiGene’s TEVIMBRA for First-Line Treatment of Advanced/Metastatic Esophageal Squamous Cell Carcinoma and Gastric or Gastroesophageal Junction Cancer Nov 27
BeiGene, Ltd. Announces Passing Away of Donald Glazer, A Board Member and the Chair of the Nominating and Corporate Governance Committee Oct 28
BeiGene, Ltd. to Report Q3, 2024 Results on Nov 13, 2024 Sep 30 BeiGene, Ltd. Appoints Shalini Sharp to Board of Directors and Member of the Audit Committee, Effective September 27, 2024 Sep 26
BeiGene Receives Israeli Ministry of Health Approval for TEVIMBRA® for the Treatment of Oesophageal Squamous Cell Carcinoma (OSCC) After Prior Chemotherapy Sep 17
BeiGene, Ltd. to Report Q2, 2024 Results on Aug 07, 2024 Jul 24 BeiGene, Ltd. Announces CFO Changes
BeiGene, Ltd. Announces CFO Changes Jul 18
BeiGene, Ltd. to Report First Half, 2024 Results on Aug 30, 2024 Jun 28 BeiGene to Present New Data from SEQUOIA Study Evaluating BRUKINSA® plus Venetoclax in High-Risk First-Line CLL/SLL at EHA2024 BeiGene, Ltd. Announces New Analyses for BRUKINSA® (zanubrutinib) At ASCO Underscore Differentiated Clinical Profile for Treatment of CLL and SLL May 25
BeiGene Highlights New Hematology Portfolio and Pipeline Data at EHA2024 May 16
BeiGene, Ltd. Receives European Commission Approval for Tislelizumab as Treatment for Non-Small Cell Lung Cancer Apr 23
BeiGene, Ltd., Annual General Meeting, Jun 05, 2024 Apr 17
BeiGene, Ltd. to Report Q1, 2024 Results on May 11, 2024 Mar 29
BeiGene, Ltd. Receives FDA Approval for TEVIMBRA for Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Prior Chemotherapy Mar 15
BeiGene, Ltd. Announces FDA Accelerated Approval of BRUKINSA for the Treatment of Relapsed or Refractory Follicular Lymphoma Mar 08
BeiGene, Ltd. to Present Clinical and Preclinical Data from Broad Portfolio and Pipeline at AACR Annual Meeting 2024 Mar 06
BeiGene, Ltd. Receives Positive CHMP Opinion for Tislelizumab as Treatment for Non-Small Cell Lung Cancer Feb 28
BeiGene, Ltd. Announces Adults Living with Chronic Lymphocytic Leukemia in Ontario and Quebec Now Have Access, Through Public Reimbursement, to BRUKINSA® (Zanubrutinib) Jan 31
Beigene, Ltd. Announces Board Changes Jan 23
BeiGene, Ltd. Announces FDA Approves Label Update for BRUKINSA (zanubrutinib) in Chronic Lymphocytic Leukemia Dec 22
BeiGene, Ltd. Receives European Commission Approval for BRUKINSA®? (zanubrutinib) for the Treatment of Relapsed or Refractory Follicular Lymphoma Nov 18
Beigene, Ltd. Receives Positive Recommendation from Nice in U.K. for Adult Patients with Chronic Lymphocytic Leukemia Oct 21
BeiGene, Ltd. Presentations at ESMO 2023 Demonstrate Robust Clinical Strategy for Tislelizumab as Monotherapy and in Combination with Pipeli Oct 17
BeiGene Receives Positive CHMP Opinion for BRUKINSA®? (zanubrutinib) in Relapsed or Refractory Follicular Lymphoma Oct 15
BeiGene Receives Positive CHMP Opinion for BRUKINSA®? (zanubrutinib) in Relapsed or Refractory Follicular Lymphoma Oct 14
U.S. FDA Accepts Biologics License Application in First-Line Advanced ESCC Sep 22
BeiGene, Ltd. Announces Positive Regulatory Updates in Europe and the U.S. After Recently Regaining Global Rights for TEVIMBRA(R) Sep 20
Beigene, Ltd. Announces Change of Chair of Audit Committee Sep 15
Beigene Announces Positive CHMP Opinion for Tislelizumab as Treatment for Advanced or Metastatic ESCC Jul 23
Beigene, Ltd. Announces FDA Acceptance of sNDA for Fifth Brukinsa(R) Indication Jul 13 BeiGene, Ltd. to Report First Half, 2023 Results on Aug 30, 2023 Jun 28
BeiGene Highlights Significant Brukinsa® (Zanubrutinib) Data at 17th International Conference on Malignant Lymphoma
Pharmacyclics LLC Files Complaint Against Beigene, Ltd. and Beigene USA, Inc Jun 16
BeiGene Highlights Promising Data from Blood Cancer Portfolio and Pipeline at the European Hematology Association Hybrid Congress Jun 10
BeiGene, Ltd. Announces Approval of BRUKINSA (Zanubrutinib) by Health Canada for the Treatment of Adult Patients with Chronic Lymphocytic Leukemia May 31
BeiGene, Ltd. Announces Presentations At the 2023 ASCO Annual Meeting Reinforce Promise Across Oncology Portfolio May 26
Beigene, Ltd. Provides Update Regarding Recent Business Developments May 09
BeiGene Announces BRUKINSA Approved in the U.S. for Chronic Lymphocytic Leukemia Jan 21
Brukinsa (Zanubrutinib) Receives Marketing Authorization for Chronic Lymphocytic Leukemia and Marginal Zone Lymphoma in Great Britain by MHRA Jan 20 BeiGene Announces Expansion of Coverage on China’s National Reimbursement Drug List Jan 19
BeiGene, Ltd. Announces Center for Drug Evaluation of the China National Medical Products Administration Accepts Supplemental Biologics License Application Jan 07 BeiGene Announces Acceptance of 12th Regulatory Submission in China for PD-1 Inhibitor Tislelizumab Dec 31
Beigene, Ltd.'S Brukinsa Demonstrated Superior Progression-Free Survival over Imbruvica (Ibrutinib) in Chronic Lymphocytic Leukemia in Late-Breaker At ASH Dec 14
Beigene to Present Final Pfs Results from Alpine Trial Demonstrating Superior Pfs for Brukinsa® Versus Imbruvica® in Late-Breaking Oral Session At Ash 2022 Nov 23
Beigene, Ltd. Announces Change of Co-Chair of Scientific Advisory Committee Nov 22
BeiGene Receives European Commission Approval for Brukinsa® (Zanubrutinib) for the Treatment of Adults with Chronic Lymphocytic Leukemia (Cll) Nov 18
Beigene, Ltd. Announces Brazil Approvals for Brukinsa® as A Treatment for Rare Blood Cancers Nov 11
Abbisko Therapeutics Co., Ltd. Completes First Patient Enrollment in Phase II Clinical Trial for Investigational Pan-FGFR Inhibitor ABSK091 in Combination with Anti-PD-1 Antibody Tislelizumab Developed by BeiGene, Ltd. in Urothelial Carcinoma Nov 05
BeiGene Receives European Commission Approval for BRUKINSA(R) (zanubrutinib) for the Treatment of Adults with Marginal Zone Lymphoma Nov 03
BeiGene, Ltd. Expands Reach of its Innovative BTK Inhibitor with Recent Regulatory Approvals in Latin America Oct 27
BeiGene Receives Positive CHMP Opinion for BRUKINSA® (zanubrutinib) for the Treatment of Adults With CLL Oct 15
Beigene Announces Positive Topline Results from Final Progression-Free Survival Analysis of Brukinsa® (Zanubrutinib) Compared to Imbruvica® (Ibrutinib) in Phase 3 Chronic Lymphocytic Leukemia (Cll) Trial Oct 13 NICE Recommends Beigene’s BRUKINSA® (Zanubrutinib) for Patients with Waldenström’s Macroglobulinemia Who Have Had At Least One Treatment
Beigene, Ltd. Announces Appointment of Member of Compensation Committee Sep 15
BeiGene Announces Data Presentations at ESMO 2022 Including Late-Breaking Oral Presentation for Tislelizumab in First-Line Unresectable Hepatocellular Cancer Sep 10
BeiGene Announces Acceptance of 11th Regulatory Submission for PD-1 Inhibitor Tislelizumab in China Aug 24
BeiGene Announces Positive Global Phase 3 Trial Results for PD-1 Inhibitor Tislelizumab in First-Line Unresectable Hepatocellular Cancer Aug 10
Beigene Provides Regulatory Update on the U.S. Biologics License Application (Bla) for Pd 1 Inhibitor Tislelizumab in 2L Escc Jul 15
BeiGene, Ltd. Appoints Chan Lee as General Counsel, July 18 2022 Jul 14
Leap Therapeutics and BeiGene, Ltd. Announces Initiation of New DKN-01 Clinical Trials in Gastric Cancer, Colorectal Cancer and Endometrial Cancer Jul 13
BeiGene Announces Late-Breaking Data at ESMO GI Showing Overall Survival Benefit for Tislelizumab Plus Chemotherapy in First-Line Advanced or Metastatic Esophageal Squamous Cell Carcinoma Jul 01
Beigene, Ltd. Announces Executive Changes Jun 23
Beigene Announces Acceptance of Supplemental Biologics License Application in China for Anti-PD-1 Inhibitor Tislelizumab Jun 22 Ministry of Health in Kuwait Approves Beigene, Ltd.'s BRUKINSA™ (Zanubrutinib) in 50 Markets
BeiGene, Ltd. Announces NMPA Grants its Anti-PD-1 Antibody Tislelizumab Approval for First-Line Treatment of Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer and Conditional Approval for Treatment of Patients with Hepatocellular Carcinoma Jun 11
Beigene Announces the Approval in China of BLINCYTO® for Injection for Pediatric Patients with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia May 05
BeiGene, Ltd., Annual General Meeting, Jun 22, 2022 May 02
BeiGene to Present Clinical Data from Innovative Oncology Portfolio at 2022 ASCO Annual Meeting Apr 28
BeiGene, Ltd. to Report Q1, 2022 Results on May 05, 2022 Apr 22
BeiGene Presents Updated Results from Phase 3 RATIONALE-309 Trial of PD-1 Inhibitor Tislelizumab in First-Line RM-NPC in Virtual ASCO Plenary Series Apr 20
BeiGene, Ltd. Announces China National Medical Products Administration Approves Tislelizumab for Patients with Second-Line Esophageal Squamous Cell Carcinoma Apr 16
Beigene Announces IRC Determines Brukinsa® (Zanubrutinib) Demonstrates Superior Overall Response Rate Versus Ibrutinib in Final Response Analysis of ALPINE Trial in Chronic Lymphocytic Leukemia Apr 12
BeiGene to Present Clinical Results and Biomarker Data on Tislelizumab in Solid Tumors at the AACR Annual Meeting 2022 Apr 09
Beigene, Ltd. Announces European Medicines Agency Acceptance of Marketing Authorization Applications for Tislelizumab for the Treatment of Patients with ESCC and NSCLC Apr 07 BeiGene, Ltd. Announces Resignation of Jane Huang, Chief Medical Officer
BeiGene, Ltd. Announces Appointment of Margaret Han Dugan as Member of the Commercial and Medical Affairs Advisory Committee of its Board of Directors Mar 01
BeiGene Announces U.S. FDA Acceptance of Supplemental New Drug Application for BRUKINSA (zanubrutinib) in Chronic Lymphocytic Leukemia Feb 24
Beigene, Ltd. Announces Approval for Brukinsa (Zanubrutinib) by Swissmedic for Treatment of Adult Patients with Waldenström’s Macroglobulinemia Feb 18 BeiGene, Ltd. to Report Fiscal Year 2021 Final Results on Mar 31, 2022 BeiGene, Ltd. Announces Executive Changes Feb 05
BeiGene, Ltd. Announces Management Changes Feb 03
BeiGene, Ltd. Announces Board Appointments Feb 02 주주 수익률 688235 CN Biotechs CN 마켓 7D -0.5% -1.9% -1.2% 1Y 18.5% -16.2% 11.8%
전체 주주 수익률 보기
수익률 대 산업: 688235 지난 1년 동안 -16.2 %를 반환한 CN Biotechs 산업을 초과했습니다.
수익률 대 시장: 688235 지난 1년 동안 11.8 %를 반환한 CN 시장을 초과했습니다.
가격 변동성 Is 688235's price volatile compared to industry and market? 688235 volatility 688235 Average Weekly Movement 7.3% Biotechs Industry Average Movement 8.8% Market Average Movement 8.7% 10% most volatile stocks in CN Market 12.8% 10% least volatile stocks in CN Market 5.7%
안정적인 주가: 688235 는) 지난 3개월 동안 큰 가격 변동성이 없었습니다.
시간에 따른 변동성: 688235 의 주간 변동성 ( 7% )은 지난 1년 동안 안정적인 모습을 보였습니다.
회사 소개 종양학 회사인 베이진은 미국, 중국, 유럽 및 전 세계에서 암 환자를 위한 다양한 치료법을 발견하고 개발하는 데 주력하고 있습니다. 다양한 혈액암 치료를 위한 브루톤 티로신 키나제(BTK) 저분자 억제제인 브루킨사, 다양한 고형암 및 혈액암 치료를 위한 항 PD-1 항체 면역 치료제인 테빔브라, 다양한 고형암 치료를 위해 단독 요법 및 병용 요법으로 평가 중인 PARP1 및 PARP2 효소의 선택적 저분자 억제제인 파트루빅스가 상용 단계 제품에 포함돼 있습니다. 이 회사의 임상 단계 제품은 저분자 Bcl-2 억제제인 BGB-11417, 야생형 및 돌연변이 BTK에 활성인 BTK 표적 키메라 분해 활성화 화합물인 BGB-16673, BGB-10188, Bcl-2 억제제인 BGB-21447, TIGIT 억제제인 Ociperlimab(BGB-A1217), 이중 특이적 HER2 표적 항체인 자니다타맙 등으로 구성돼 있습니다; TIM-3 억제제인 서제비클리맙(BGB-A425); OX40 작용제 항체인 BGB-A445; HPK1 저분자 억제제인 BGB-15025; SMAC 모방체인 BGB-24714; HPK-1 억제제인 BGB-26808; RAF 억제제인 리피라페닙과 BGB-3245; 항 CCR8 항체인 BGB-30813; BGB-A3055; CDK-4 억제제인 BGB-43395 등을 개발하고 있습니다.
자세히 보기 BeiGene, Ltd. 기본 사항 요약 BeiGene 의 수익과 매출은 시가총액과 어떻게 비교하나요? 688235 기본 통계 시가총액 CN¥136.82b 수익(TTM ) -CN¥5.99b 수익(TTM ) CN¥23.51b
수익 및 수익 최신 수익 보고서의 주요 수익성 통계(TTM) 688235 손익 계산서(TTM ) 수익 CN¥23.51b 수익 비용 CN¥3.84b 총 이익 CN¥19.67b 기타 비용 CN¥25.66b 수익 -CN¥5.99b
주당 순이익(EPS) -56.41 총 마진 83.67% 순이익 마진 -25.50% 부채/자본 비율 29.6%
688235 의 장기적인 성과는 어땠나요?
과거 실적 및 비교 보기
기업 분석 및 재무 데이터 현황 데이터 마지막 업데이트(UTC 시간) 기업 분석 2024/12/22 00:52 장 마감 주가 2024/12/20 00:00 수익 2024/09/30 연간 수익 2023/12/31
데이터 소스 기업 분석에 사용된 데이터는 S&P Global Market Intelligence LLC의 데이터입니다. 이 보고서를 생성하기 위해 분석 모델에 사용된 데이터는 다음과 같습니다. 데이터는 정규화되어 있으므로 소스가 제공되기까지 지연이 발생할 수 있습니다.
패키지 데이터 기간 미국 소스 예시 * 회사 재무 10년 애널리스트 컨센서스 추정치 +3년 시장 가격 30년 소유권 10년 관리 10년 주요 개발 사항 10년
* 미국 증권의 경우, 미국 외 지역의 규제 양식 및 출처가 사용된 예입니다.
명시되지 않는 한 모든 재무 데이터는 1년을 기준으로 하지만 분기별로 업데이트됩니다. 이를 후행 12개월(TTM) 또는 최근 12개월(LTM) 데이터라고 합니다. 여기에서 자세히 알아보세요.
분석 모델 및 눈송이 이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 Github 페이지에서 확인할 수 있으며, 보고서 사용 방법에 대한 가이드와 튜토리얼도 유튜브에서 확인할 수 있습니다.
Simply 월스트리트 분석 모델을 설계하고 구축한 세계적인 수준의 팀에 대해 알아보세요.
산업 및 부문 메트릭 업계 및 섹션 지표는 Simply Wall St에서 6시간마다 계산되며, 자세한 내용은 확인할 수 있습니다.
애널리스트 출처 BeiGene, Ltd. 57 애널리스트 중 29 애널리스트가 보고서의 입력 자료로 사용된 매출 또는 수익 추정치를 제출했습니다. 애널리스트의 제출 자료는 하루 종일 업데이트됩니다.
분석가 교육기관 Brian Skorney Baird Michael Meng BOCI Research Ltd. Yonglin Yan BOCI Research Ltd.
54 더 많은 분석가 보기 